Mirtazapina Tarbis (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity. Its strong H1‑histamine receptor antagonism also contributes to sedation and appetite stimulation, together producing an overall antidepressant effect.

The appropriate dose of mirtazapine is individualized by the prescribing clinician based on factors such as the severity of depression, patient age, liver function, concomitant medications, and response to therapy. No fixed regimen is provided here; the prescriber will set the dosage according to clinical judgment.

Safety data for mirtazapine in pregnancy and lactation are limited. It is generally classified as a drug with unknown pregnancy risk, and use is only considered when the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Mirtazapina Tarbis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team will then reply with pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, whereas SSRIs primarily inhibit serotonin reuptake. Mirtazapine’s dual action on norepinephrine and serotonin, plus its antihistaminic effect, often results in pronounced sedation and weight gain, which can be advantageous for patients with insomnia or loss of appetite. SSRIs typically have a lower risk of weight gain but may cause sexual dysfunction.

Mirtazapina Tarbis should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children. No refrigeration is required for this oral dosage form.

Mirtazapina Tarbis is taken orally, usually once daily in the evening to take advantage of its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed. The exact timing and any food considerations are determined by the prescribing clinician.

Serious risks include the potential for agranulocytosis or severe neutropenia, severe skin reactions such as Stevens‑Johnson syndrome, and the emergence of suicidal thoughts or worsening depression, especially during the initial weeks of therapy. Patients should seek immediate medical attention if they notice signs of infection, rash, or mood changes.

Mirtazapine is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should also be avoided in patients currently taking monoamine oxidase inhibitors (MAOIs) or those with a history of severe allergic reactions to similar agents. Caution is advised for patients with uncontrolled hypertension, severe liver impairment, or a history of bipolar disorder.